Senseonics (NYSE:SENS) Stock Price Up 8.4% – Time to Buy?

Senseonics Holdings, Inc. (NYSE:SENS)’s stock price was up 8.4% on Friday . The company traded as high as $1.12 and last traded at $1.10. Approximately 4,920,939 shares changed hands during trading, a decline of 78% from the average daily volume of 22,190,742 shares. The stock had previously closed at $1.01.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. StockNews.com initiated coverage on shares of Senseonics in a research report on Thursday, December 26th. They issued a “sell” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $2.00 price objective on shares of Senseonics in a research note on Friday, November 15th.

Senseonics Trading Up 11.9 %

The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The firm has a market cap of $672.72 million, a P/E ratio of -8.69 and a beta of 0.64. The firm has a 50 day simple moving average of $0.50 and a 200 day simple moving average of $0.42.

Senseonics (NYSE:SENS) last released its quarterly earnings data on Thursday, November 7th. The company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.01). The firm had revenue of $4.26 million during the quarter, compared to the consensus estimate of $4.02 million. Senseonics had a negative net margin of 362.30% and a negative return on equity of 842.25%. On average, equities research analysts predict that Senseonics Holdings, Inc. will post -0.14 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CFO Frederick T. Sullivan acquired 124,933 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were bought at an average cost of $0.38 per share, for a total transaction of $47,474.54. Following the completion of the transaction, the chief financial officer now owns 2,478,844 shares in the company, valued at approximately $941,960.72. This trade represents a 5.31 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Timothy T. Goodnow purchased 315,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The stock was bought at an average cost of $0.31 per share, with a total value of $97,650.00. Following the purchase, the chief executive officer now owns 11,310,355 shares in the company, valued at approximately $3,506,210.05. This represents a 2.86 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 3.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Senseonics

Hedge funds have recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of Senseonics by 48,267.2% during the 3rd quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after purchasing an additional 167,970 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Senseonics by 3.2% during the third quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after buying an additional 179,103 shares during the last quarter. GSA Capital Partners LLP purchased a new position in shares of Senseonics in the third quarter worth about $117,000. Cubist Systematic Strategies LLC lifted its stake in shares of Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after acquiring an additional 85,501 shares during the last quarter. Finally, Ridgecrest Wealth Partners LLC purchased a new stake in Senseonics during the 4th quarter valued at about $60,000. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.